A Phase II Study of BAY 43-9006/Gemcitabine for Advanced Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2013
At a glance
- Drugs Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2013 Planned number of patients changed from 12 to 35 as reported by ClinicalTrials.gov.
- 19 Dec 2007 Status changed from suspended to in progress.